Increased oxidative stress has been strongly linked to conditions like atherosclerosis and age-related macular degeneration (AMD) -- the most common cause of blindness among the elderly in western societies. Oxidative stress is the process in which proteins, lipids and DNA damaged by oxygen free radicals and related cellular waste accumulate, prompting an inflammatory response from the body's innate immune system that results in chronic disease.
In the October 6, 2011 issue of Nature
, researchers at the University of California, San Diego School of Medicine, as part of an international collaborative effort, identify a key protein that binds to a molecule generated by oxidative stress, blocking any subsequent inflammatory immune response. The scientists, led by senior author Christoph J. Binder, assistant adjunct professor of medicine at UC San Diego, principal investigator at the Center for Molecular Medicine of the Austrian Academy of Sciences and professor at the Medical University of Vienna, say their findings reveal important insights into how the innate immune system responds to oxidative stress and might be exploited to prevent and treat AMD and other chronic inflammatory diseases.
Specifically, Binder, Joseph L. Witztum, professor of medicine at UC San Diego, and colleagues in Austria, Germany, England and Maryland discovered that when lipids (fats) in cell membranes degrade through oxidative stress, they produce a number of reactive products, including a compound called malondialdehyde (MDA), which in turn modifies other molecules to create novel oxidation-specific epitopes, the part of antigens that draws the attention and inflammatory response of the innate immune system.
The researchers noted, in particular, that MDA attracted an immune system protein called complement factor H (CFH), which bound to it, effectively blocking the uptake of MDA-modified proteins by macrophages, a type of white blood cell charged with killing and eliminating foreign invaders and substances. In in-vivo experiments, the researchers reported that CFH neutralized the inflammatory effects of MDA in mice retinas, limiting the inflammatory response associated with AMD and other chronic diseases.
They also found that a specific mutation in the CFH protein, which is associated with a four-to-seven-fold greater risk of developing AMD, greatly diminished the ability of CFH to bind to MDA.
Binder said the findings further demonstrate the innate immune system's important but not fully appreciated "house-keeping function, defending against endogenous waste products and not just against foreign microbial products."
Beyond that, he said the distinctive, protective role of CFH represents a potential new therapeutic approach for treating AMD, heart disease and other chronic conditions. "This activity of CFH can be used for the development of neutralizing agents to mimic this function."